- Home
- IONS vs BEP Comparison
IONS vs BEP Comparison
Compare IONS & BEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- BEP
- Stock Information
- Founded
- IONS 1989
- BEP 1999
- Country
- IONS United States
- BEP Canada
- Employees
- IONS N/A
- BEP N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- BEP Electric Utilities: Central
- Sector
- IONS Health Care
- BEP Utilities
- Exchange
- IONS Nasdaq
- BEP Nasdaq
- Market Cap
- IONS 6.8B
- BEP 7.3B
- IPO Year
- IONS 1991
- BEP N/A
- Fundamental
- Price
- IONS $61.23
- BEP $24.88
- Analyst Decision
- IONS Buy
- BEP Buy
- Analyst Count
- IONS 17
- BEP 8
- Target Price
- IONS $67.88
- BEP $31.25
- AVG Volume (30 Days)
- IONS 3.1M
- BEP 469.2K
- Earning Date
- IONS 07-30-2025
- BEP 08-01-2025
- Dividend Yield
- IONS N/A
- BEP 5.92%
- EPS Growth
- IONS N/A
- BEP N/A
- EPS
- IONS N/A
- BEP N/A
- Revenue
- IONS $944,050,000.00
- BEP $6,174,000,000.00
- Revenue This Year
- IONS $24.30
- BEP $18.12
- Revenue Next Year
- IONS $7.39
- BEP $5.94
- P/E Ratio
- IONS N/A
- BEP N/A
- Revenue Growth
- IONS 16.05
- BEP 12.75
- 52 Week Low
- IONS $23.95
- BEP $19.29
- 52 Week High
- IONS $62.08
- BEP $29.56
- Technical
- Relative Strength Index (RSI)
- IONS 83.44
- BEP 44.45
- Support Level
- IONS $42.13
- BEP $24.48
- Resistance Level
- IONS $62.08
- BEP $25.99
- Average True Range (ATR)
- IONS 2.11
- BEP 0.47
- MACD
- IONS 2.09
- BEP 0.01
- Stochastic Oscillator
- IONS 95.83
- BEP 26.49
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.